Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: amato cm. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.
Tobin RP, Jordan KR, Kapoor P, Spongberg E, Davis D, Vorwald VM, Couts KL, Gao D, Smith DE, Borgers JSW, Robinson S, Amato C, Gonzalez R, Lewis KD, Robinson WA, Borges VF, McCarter MD. Tobin RP, et al. Front Oncol. 2019 Nov 8;9:1223. doi: 10.3389/fonc.2019.01223. eCollection 2019. Front Oncol. 2019. PMID: 31781510 Free PMC article.
Circulating CD8+ mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients.
Vorwald VM, Davis DM, Van Gulick RJ, Torphy RJ, Borgers JS, Klarquist J, Couts KL, Amato CM, Cogswell DT, Fujita M, Castleman MJ, Davis T, Lozupone C, Medina TM, Robinson WA, Gapin L, McCarter MD, Tobin RP. Vorwald VM, et al. Among authors: amato cm. Clin Transl Immunology. 2022 Jan 10;11(1):e1367. doi: 10.1002/cti2.1367. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35028137 Free PMC article.
IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC. Hintzsche J, et al. J Am Med Inform Assoc. 2016 Jul;23(4):721-30. doi: 10.1093/jamia/ocw022. Epub 2016 Mar 28. J Am Med Inform Assoc. 2016. PMID: 27026619 Free PMC article.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. Mukherjee N, et al. Among authors: amato cm. Cell Death Dis. 2020 Jun 8;11(6):443. doi: 10.1038/s41419-020-2646-2. Cell Death Dis. 2020. PMID: 32513939 Free PMC article.
43 results